1. Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin
- Author
-
Yuichi Kojima, Takako Miyazaki, Kazuhide Higuchi, Yuki Hirata, Yasuhiro Ueda, Shiro Nakamura, Hiroyuki Tsujimoto, Kazuki Kakimoto, Ryoji Koshiba, Toshihisa Takeuchi, Kazuhiro Ota, Naohiko Kinoshita, Yasuyoshi Tanaka, and Hideki Tawa
- Subjects
Male ,medicine.medical_specialty ,Anemia ,medicine.drug_class ,Vonoprazan ,Proton-pump inhibitor ,Comorbidity ,Hematocrit ,030226 pharmacology & pharmacy ,Gastroenterology ,Esomeprazole ,Hemoglobins ,03 medical and health sciences ,0302 clinical medicine ,Lactobacillales ,Internal medicine ,Gastrins ,medicine ,Humans ,Pyrroles ,Pharmacology (medical) ,Prospective Studies ,030212 general & internal medicine ,Intestinal Mucosa ,Aged ,Gastrin ,Aged, 80 and over ,Pharmacology ,Sulfonamides ,Aspirin ,Dose-Response Relationship, Drug ,medicine.diagnostic_test ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Proton Pump Inhibitors ,General Medicine ,Middle Aged ,medicine.disease ,Gastrointestinal Microbiome ,Case-Control Studies ,Gastric acid ,Female ,Gastrointestinal Hemorrhage ,business ,Polymorphism, Restriction Fragment Length ,medicine.drug - Abstract
Low-dose aspirin (LDA) administration prevents cerebral infarction and myocardial infarction, but many studies found an association with mucosal injury. Proton-pump inhibitors (PPIs) can prevent gastric and duodenal mucosal damage, but they may exacerbate small-intestinal mucosal injury by altering the microbiota. We aimed to assess the effect of PPIs on the intestinal flora of LDA users. Thirty-two recruited patients, who received LDA (100 mg/day) but did not take PPIs, were divided into 15 patients additionally receiving esomeprazole (20 mg/day) and 17 patients additionally receiving vonoprazan (10 mg/day). On days 0, 30, 90, and 180, the microbiota of each patient was examined by terminal restriction fragment length polymorphism analysis, and the serum gastrin, hemoglobin, and hematocrit levels were measured. Additional PPI administration increased the proportion of Lactobacillales in the microbiota of LDA users. This trend was more prevalent in the vonoprazan group (p
- Published
- 2021